Synchronous pancreatic and gastric metastasis from an ovarian adenocarcinoma diagnosed by endoscopic ultrasound-guided fine-needle aspiration

Metastasis of ovarian carcinoma to the stomach [1–5] or pancreas [6, 7] is uncommon. Furthermore, synchronous metastasis of ovarian adenocarcinoma to the stomach and pancreas has never been reported. We report here the detection of synchronous metastasis to both the stomach and pancreas from a resected ovarian papillary serous cystadenocarcinoma.

At 25 months after gynecological surgery, a gastric submucosal mass and pancreatic masses were noted on follow-up computed tomography in an asymptomatic 51-year-old woman. Contrast-enhanced computed tomography showed a 4.6×4.2-cm intramural mass (yellow arrows) in the gastric antrum suggestive of a gastric submucosal tumor (● Fig. 1a) and a 1.0×1.0-cm mass (yellow arrows) in the pancreatic body (● Fig. 1b). The serum cancer antigen 125 (CA-125) level was high (89 U/mL; normal <35 U/mL).

The patient underwent esophagogastroduodenoscopy (EGD), which showed a 3-cm subepithelial mass at the antrum (● Fig. 2). Endoscopic ultrasound (EUS) demonstrated that the lesion was located mainly in the fourth layer (● Fig. 3). In addition, two pancreatic lesions, measuring 7×5 mm and 4×3 mm, were identified in the pancreatic body (● Fig. 4). EUS-guided fine-needle aspiration (EUS-FNA) of the gastric and pancreatic lesions was performed, and microscopic examination showed a group of cells with rounded borders and round to oval nuclei in a papillary arrangement (● Fig. 5).
Immunohistochemical study revealed positivity for cytokeratin 7 (++) , CA-125 (+) , estrogen receptor (++), progesterone receptor (+), and CD56 (++), and negativity for cytokeratin 20 (-) and CDX-2 (-). The pathological features were similar to those of the previous ovarian lesion. The final pathological diagnosis was metastatic tumor from a primary ovarian carcinoma.

In conclusion, a possible diagnosis of gastric and pancreatic metastasis of ovarian papillary serous adenocarcinoma should be kept in mind in a patient with an unknown primary lesion, even one with a remote history of ovarian malignancy. EUS-FNA in conjunction with immunohistochemistry is a useful tool for diagnosing metastatic lesions.

References

Competing interests: None

Corresponding author
Masayuki Kitano, MD, PhD
Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-sayama, Japan
Fax: +81-72-366-0206
m-kitano@med.kindai.ac.jp

Bibliography
DOI http://dx.doi.org/10.1055/s-0034-1393649
Endoscopy 2015; 47: E596–E597
© Georg Thieme Verlag KG
Stuttgart · New York
ISSN 0013-726X